The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma.
 
Michal Sternschuss
No Relationships to Disclose
 
Karissa Whiting
No Relationships to Disclose
 
Alyssa Arbuiso
No Relationships to Disclose
 
Aditi Gupta
No Relationships to Disclose
 
Eric Bent
Stock and Other Ownership Interests - Unity Biotechnology
 
Nathaniel Alvarez
No Relationships to Disclose
 
Ashley Regazzi
No Relationships to Disclose
 
Stanley Liang
Employment - Memorial Sloan-Kettering Cancer Center
 
Firas Ahmed
No Relationships to Disclose
 
Oguz Akin
Stock and Other Ownership Interests - Ezra AI
 
Volkan Beylergil
Consulting or Advisory Role - Clario
 
Samuel Funt
Employment - ByHeart (I)
Stock and Other Ownership Interests - 76Bio (I); Allogene Therapeutics; Doximity; IconOVir Bio (I); Kite, a Gilead company; Kronos Bio; Neogene Therapeutics (I); Urogen pharma (I); Vida Ventures (I)
Consulting or Advisory Role - BioNtech; Generate Biomedicines; Immunai; Merck
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Dean Bajorin
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
 
Gopa Iyer
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Research Funding - AADi (Inst); Flare Therapeutics (Inst); Janssen (Inst); Loxo/Lilly (Inst); Pfizer (Inst)
 
Irina Ostrovnaya
Consulting or Advisory Role - Ataraxis
 
David Aggen
Consulting or Advisory Role - Adaptimmune; Alphasights; Aptitude Health; Astellas Pharma; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Century Therapeutics; Curio Science; Guidepoint Global Advisors; MJH Life Sciences; Pfizer; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Jonathan Rosenberg
Honoraria - MashupMD; NCCN/Pfizer; Pfizer; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Century Therapeutics; EMD Serono; Generate Biomedicines; Gilead Sciences; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Samsung Bioepis; Seagen; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Lilly; Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Amplification of chromosome 1q23 to predict cancer outcomes (Inst); Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Seagen
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology